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Suberanilohydroxamic	  Acid	  (SAHA)	  Inhibits	  Collagen	  deposition	  in	  a	  
Transforming	  Growth	  Factor	  β1-­‐driven	  Precision	  Cut	  Lung	  Slice	  (PCLS)	  model	  of	  Pulmonary	  Fibrosis.	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Introduction	  and	  Objectives:	  Idiopathic	  Pulmonary	  Fibrosis	  (IPF)	  is	  a	  chronic,	  progressive	  interstitial	  lung	  
disease	  that	  is	  refractory	  to	  current	  treatment	  options.	  Transforming	  growth	  factor	  (TGF)-­‐β1	  is	  a	  key	  
pro-­‐fibrotic	  cytokine	  that	  plays	  a	  crucial	  role	  in	  IPF	  pathogenesis.	  Our	  group	  previously	  demonstrated	  
distinct	  epigenetic	  modifications	  involved	  in	  repression	  of	  the	  antifibrotic	  gene	  cyclooxygenase-­‐2	  (COX-­‐
2)	  in	  fibroblasts	  from	  IPF	  (F-­‐IPF)	  lungs	  compared	  with	  fibroblasts	  from	  non-­‐fibrotic	  lungs	  (F-­‐NL).	  
Epigenetic	  drugs	  capable	  of	  inhibiting	  DNA	  and	  histone	  modifications	  may,	  therefore,	  represent	  a	  
putative	  novel	  therapy.	  The	  aim	  of	  this	  study	  was	  to	  investigate	  the	  ability	  of	  4	  epigenetic	  inhibitors	  to	  
regulate	  TGF-­‐β-­‐driven	  fibrosis	  in	  ex	  vivo	  mouse	  lung.	  
Methods:	  A	  precision-­‐cut	  lung	  slice	  (PCLS)	  model	  of	  fibrosis	  was	  established	  using	  the	  previously	  
described	  [1]	  CC10-­‐tTS-­‐rtTA-­‐TGFβ1	  transgenic	  (tgTGF-­‐β1)	  mouse.	  The	  model	  was	  first	  assessed	  by	  
investigating	  PCLS	  overexpression	  of	  TGF-­‐β1	  in	  response	  to	  stimulation	  of	  the	  transgene	  by	  doxycycline	  
treatment.	  Gene	  expression	  of	  COX-­‐2	  and	  fibrotic	  markers	  including	  collagen	  were	  assessed	  after	  4	  days	  
of	  treatment.	  The	  anti-­‐fibrotic	  potential	  of	  4	  epigenetic	  inhibitors;	  BIX01294	  (BIX,	  inhibitor	  of	  G9a	  
histone	  methyltransferase),	  3-­‐deazaneplanocin	  A	  (DZNep,	  inhibitor	  of	  EZH2	  histone	  methyltransferase),	  
SAHA	  (inhibitor	  of	  histone	  deacetylases,	  HDACs)	  and	  Decitabine	  (DAC,	  DNA	  demethylating	  agent)	  was	  
investigated.	  Viability	  of	  PCLS	  was	  assessed	  by	  MTT	  and	  Prestoblue®	  viability	  assay.	  
Results:	  Treatment	  of	  PCLS	  from	  tgTGF-­‐β1	  mice	  with	  doxycycline	  induced	  a	  concentration-­‐dependent	  
increase	  in	  global	  TGF-­‐β1,	  pro-­‐fibrotic	  markers	  including	  collagen	  and	  pro-­‐inflammatory	  COX-­‐2,	  which	  
was	  comparable	  to	  recombinant	  TGF-­‐β1	  treatment.	  Treatment	  with	  three	  of	  the	  epigenetic	  inhibitors	  
BIX01294,	  DZNep	  and	  DAC	  did	  not	  reduce	  the	  pro-­‐fibrotic	  response	  following	  doxycycline	  treatment.	  
However	  SAHA	  demonstrated	  a	  significant	  suppressive	  effect	  on	  COX-­‐2	  and	  collagen	  expression,	  while	  
not	  directly	  affecting	  TGF-­‐β1	  transgene	  expression.	  	  
Conclusions:	  The	  data	  suggests	  that	  SAHA	  has	  the	  potential	  to	  reduce	  fibrosis	  in	  a	  TGF-­‐β1	  driven	  model	  
of	  pulmonary	  fibrosis.	  Further	  work	  is	  currently	  underway	  to	  assess	  the	  anti-­‐fibrotic	  potential	  of	  this	  
drug	  in	  tgTGF-­‐β1	  animals.	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